Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial-Reference-Cited by-同舟云学术

Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Published:2015-10-16 Issue:1 Volume:16 Page:
ISSN:1471-2369
Container-title:BMC Nephrology
language:en
Short-container-title:BMC Nephrol

Author:

Koyama Akio,Fujita Toshiro,Gejyo Fumitake,Origasa Hideki,Isono Masanao,Kurumatani Hajimu,Okada Kiyonobu,Kanoh Hiroyuki,Kiriyama Takashi,Yamada Shunsuke

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/content/pdf/10.1186/s12882-015-0130-5.pdf

Reference42 articles.

1. Xie Y, Chen X. Epidemiology, major outcomes, risk factors, prevention and -management of chronic kidney disease in China. Am J Nephrol. 2008;28:1–7.

2. Akizawa T. Current Status of Dialysis Therapy and Related Clinical Guidelines in Japan. JMAJ. 2010;53:185–7.

3. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15 Suppl 2:3–9.

4. Jin DC. Current status of dialysis therapy in Korea. Korean J Intern Med. 2011;26:123–31.

5. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kid Int. 2013;3:1–150.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy of beraprost sodium in treating chronic kidney disease: A six-month prospective study;Heliyon;2024-01

2. Expert consensus on the establishment and maintenance of native arteriovenous fistula;Chronic Diseases and Translational Medicine;2021-12

3. Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males;Clinical Drug Investigation;2021-04-28

4. Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study;Therapeutic Apheresis and Dialysis;2021-02-21

5. Prostaglandins as potential targets for the treatment of polycystic kidney disease;Prostaglandins, Leukotrienes and Essential Fatty Acids;2021-01